Press releases

Changes in Eevia Health management team - new Commercial manager

Eevia Health Plc ("Eevia" or "The Company") is welcoming Matleena Kotila as the new Commercial manager. At the same time, Tommi Kilpeläinen's contract as Scientific Product Manager was discontinued in the trial period.

Matleena Kotila is a pharmacist and has a career in the sales and marketing of pharmaceuticals, medical devices, and dietary supplements. She comes from a position in Rekitt Benckiser as a Brand activation manager. Matleena will start in Eevia on March 1st, 2023, in a new position as Commercial manager. In this position, she will be responsible for the marketing, sales, customer service, and overall customer front of Eevia.

Simultaneously, Tommi Kilpeläinen's contract as the scientific product manager was discontinued in February 2022 during the trial period, and he now moves on to a position in a large pharmaceutical company in Finland.

The Company's focus on autophagy processes in human cells remains and will be strengthened with different measures during the next few months.

"We are delighted to welcome Matleena as our new Commercial manager. She will bring the needed competence and capacity to bring our products to the nutraceutical industry. With her background in pharmaceuticals, she brings in the knowledge of pharmacology and chemistry, which supports the robust technical inbound marketing model we employ in Eevia.

At the same time, we are sad to see Tommi leaving. Even in the short time he was here, he helped us significantly by focusing more stringently on extracts that support cellular health and autophagy. Eevia wishes Tommi well in the future.

The demand for products with efficacy in autophagy induction (cellular recycling), and cognitive health will skyrocket in the future, and we have other initiatives to ensure progress in this direction," comments Stein Ulve, CEO of Eevia Health Plc.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          


Telephone: +358 400 22 5967  


Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  or follow Eevia Health on LinkedIn@EeviaHealth.


Eevia Health ("Eevia" or "The Company") received a 13K USD /12KEUR sales order for the elderberry extract Feno-Sambucus™ 7 Organic.


Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from a European customer of c. 41 KEUR for an organically certified bilberry extract.


Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the first quarter of 2023.


Eevia Health Plc ("Eevia" or "The Company") is promoting its products and value proposition by exhibiting at Vitafoods 2023, a key nutraceutical tradeshow in Geneva, Switzerland between 9 - 11 May 2023


Eevia Health Abp ("Eevia Health" or the "Company") has appointed Mangold Fondkommission to act as a liquidity provider for the company's shares. The assignment commences on Wednesday, May 4th, 2023.


Eevia Health Plc, ("Eevia" or "The Company"), has received a first sales order from a new customer in Germany of c. 11 KEUR for Feno-Myrtillus® 36 Organic, an organically certified bilberry extract


Eevia Health Plc ("Eevia" or "The Company") has decided to adjust the planned time for several financial events in 2023.


Eevia Health ("Eevia" or "The Company") received a 450 KSEK / 40 KEUR sales order for the Feno-Sambucus™ from its Australian distributor Ingredient Plus. The order is the second order from an Australian brand owner.


Due to a language setting choice in our Cision News portal with both English and Finnish chosen in the original press release, the press release did not go out automatically on all channels at the same time. To ensure the release is available on all channels, we re-release the press release. There are no changes to the substance of the release.

Eevia Health Plc, ("Eevia" or "The Company"), received several new sales orders totaling c. 23.8 MSEK / 2.1 MEUR from an International nutraceutical brand owner for an extract ingredient with immune health properties.


Eevia Health Plc, ("Eevia" or "The Company"), received several new sales orders totaling c. 23.8 MSEK / 2.1 MEUR from an International nutraceutical brand owner for an extract ingredient with immune health properties.